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ABSTRACT
Disruption of minor spliceosome functions underlies
several genetic diseases with mutations in the minor
spliceosome-specific small nuclear RNAs (snRNAs)
and proteins. Here, we define the molecular outcome
of the U12 snRNA mutation (84C>U) resulting in an
early-onset form of cerebellar ataxia. To understand
the molecular consequences of the U12 snRNA mu-
tation, we created cell lines harboring the 84C>T mu-
tation in the U12 snRNA gene (RNU12). We show
that the 84C>U mutation leads to accelerated de-
cay of the snRNA, resulting in significantly reduced
steady-state U12 snRNA levels. Additionally, the mu-
tation leads to accumulation of 3′-truncated forms
of U12 snRNA, which have undergone the cytoplas-
mic steps of snRNP biogenesis. Our data suggests
that the 84C>U-mutant snRNA is targeted for decay
following reimport into the nucleus, and that the U12
snRNA fragments are decay intermediates that result
from the stalling of a 3′-to-5′ exonuclease. Finally, we
show that several other single-nucleotide variants in
the 3′ stem-loop of U12 snRNA that are segregating
in the human population are also highly destabiliz-
ing. This suggests that the 3′ stem-loop is important
for the overall stability of the U12 snRNA and that ad-
ditional disease-causing mutations are likely to exist
in this region.
INTRODUCTION
Defects in pre-mRNA splicing are increasingly recognized
as important contributors to human disease. While the ma-
jority of disease-causing mRNA splicing defects result from
mutations in cis-acting signals necessary for intron recog-
nition, a large number of disease-causing mutations have
also been identified in the core components of the spliceo-
some and auxiliary splicing factors. A significant portion of
human disease-causing mutations in the core spliceosome
components have been described in the minor spliceosome.
The minor spliceosome, also called the U12-dependent
spliceosome, is a pre-mRNA splicing machinery that recog-
nizes and excises <0.5% of introns in the human genome,
while the major spliceosome (U2-dependent spliceosome)
excises >99% of the introns. Both spliceosomes coexist in
the cells of most metazoan species and show similar over-
all architecture, assembly pathways, and catalytic mecha-
nisms. The main architectural difference between the two
spliceosomes lies in the composition of small nuclear ri-
bonucleoproteins (snRNPs) and specifically in the composi-
tion of their small nuclear RNA (snRNA) components. U1,
U2, U4 and U6 snRNAs/snRNPs are unique to the ma-
jor spliceosome while the respective U11, U12, U4atac and
U6atac snRNAs/snRNPs are specific to the minor spliceo-
some (1–5). In contrast, the U5 snRNP is shared between
the two spliceosomes. Despite divergence at the sequence
level, analogous snRNAs in the two spliceosomes fold into
similar secondary structures (3).
Minor spliceosome-specific snRNAs are present as
single-copy genes in mammalian genomes, unlike the corre-
sponding genes encoding snRNA components of the major
spliceosome that are present as multigene arrays/families
(6). Additionally, mammalian genomes also code for vari-
ants of all spliceosomal snRNAs that divert from ‘canoni-
cal’ snRNA sequences, and in most cases are of unknown
functional significance (7). In addition to four unique snR-
NAs, the minor spliceosome contains a set of proteins not
present in the major spliceosome (8,9), and vice versa,
the majority of spliceosomal proteins are thought to asso-
ciate with both spliceosomes. Although the overall splicing
chemistry is similar between the two spliceosomes, intron
recognition in the major spliceosome is carried out by in-
dividual U1 and U2 snRNPs, while the minor spliceosome
analogs U11 and U12 function together as an intron recog-
nition complex known as the U11/U12 di-snRNP (10,11).
Consistent with the different mechanisms of intron recogni-
tion, the protein components known to be unique to one of
the spliceosomes are found in the U11/U12 di-snRNP and
the U1 and U2 snRNPs (8,9).
Mutations in both protein and snRNA components that
are specific to the minor spliceosome have been linked to
five hereditary diseases while one disease is caused by so-
matic mutations (12). In the majority of inherited diseases,
the patients are compound heterozygotes carrying two sep-
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arate mutations in the same locus. However, only with two
diseases the underlying mechanisms have been explored.
One of those is a member of a group of three diseases,
which are all caused by mutations in the RNU4ATAC lo-
cus, encoding U4atac snRNA. Depending on the muta-
tions, the patients suffer from any of three distinct disor-
ders with partially overlapping phenotypes: Microcephalic
Osteodysplastic Primordial Dwarfism type I, also known as
Taybi–Linder syndrome (MOPD I/TALS; 13,14), Roifman
syndrome (RFMN; 15) and Lowry Wood syndrome (LWS;
16). In this case, Jafarifar et al. (17) carried out an exten-
sive analysis of point mutations related to MOPD I/TALS,
and reported that the majority of the mutations disrupt
the binding site of the 15.5K protein, leading to disruption
of the U4atac/U6atac.U5 tri-snRNP. Additionally, one of
the mutations leads to reduced U4atac snRNA levels pre-
sumably due to disruption of the binding site for Sm pro-
teins (Sm site). In the other case, we investigated compound
heterozygous mutations in the RNPC3 gene, encoding the
U11/U12-65K protein, that result in isolated growth hor-
mone deficiency (IGHD; 18,19). We found that the disease
is an outcome of two effects: reduction of mRNA levels
due to nonsense-mediated decay, and reduced affinity of the
U11/U12-65K protein to U12 snRNA because of a protein
folding defect (19). Together these lead to reduced U11/U12
di-snRNP levels, causing a splicing defect.
Recently, an 84C>T mutation in the U12 snRNA gene
(RNU12) has been shown to cause an early-onset form of
cerebellar ataxia (EOCA) with autosomal recessive inher-
itance (20). EOCA patients that are homozygous for the
84C>T mutation display hypotonia at infancy, speech and
learning difficulties, delayed motor development, ataxia,
and cerebellar hypoplasia and degeneration (20). Interest-
ingly, the 84C>U mutation is located a few nucleotides
downstream of the Sm site at the base of the long 3′ ter-
minal stem-loop III (SLIII) of U12 snRNA. Therefore, the
mutation is located away from the key functional elements
of U12 snRNA that interact with the branch point se-
quence of the intron and the U6atac snRNA during splic-
ing (Figure 1A). The SLIII itself is important for the sta-
bility of the U11/U12 di-snRNP complex, as it is bound
by the U11/U12-65K protein that serves as the bridge be-
tween U11 and U12 snRNPs (18,19,21,22). Consistently,
the U11/U12 di-snRNP complex is disrupted by IGHD-
causing mutations in the U11/U12-65K protein (18); how-
ever, location of the 84C>U U12 snRNA mutation does not
suggest a similar molecular mechanism, as the binding site
for the 65K protein is predicted to remain intact.
Here, we investigate the mechanistic consequences of the
U12 84C>U mutation that causes early-onset cerebellar
ataxia. We show that this mutation leads to accelerated de-
cay of the U12 snRNA in several human cell lines. Further-
more, we detect several stable decay intermediates that lack
the SLIII of U12 snRNA in cells carrying the disease mu-
tation. Interestingly, the same decay intermediates can also
be detected at low levels in wild-type cells, suggesting that
the same decay process is part of the natural biogenesis or
turnover of U12 snRNA. Additionally, we analyzed U12
variants carrying single nucleotide point mutations within
the SLIII region. We identified several U12 SNP variants
segregating in the human population that destabilize the
U12 snRNA similarly to the EOCA mutation. This sug-
gests that there may be additional U12 mutations leading
to EOCA or similar human diseases.
MATERIALS AND METHODS
Plasmid construction
To create the pUC19-RNU12 plasmid, the RNU12 gene,
including 942 bp of upstream and 343 bp of downstream
sequence was amplified from HEK293 genomic DNA
using primers RNU12-BamHI-F and RNU12-HindIII-R
and cloned into the BamHI and HindIII sites of the
pUC19 vector. Subsequently, 15 extra nucleotides (5′-
ATGAGATAGTGATAC-3′) were inserted into the 5′ end
of the U12 snRNA sequence by PCR, resulting in pUC19-
RNU12-5′tag. The 84C>T mutation and other mutations
were introduced into the pUC19-RNU12-5′tag plasmid by
site-directed mutagenesis. To create Target-AID-RNU12
plasmid, we used whole-plasmid PCR to replace the existing
guide RNA sequence in plasmid pcDNA3.1 pCMV-nCas-
PmCDA1-ugi pH1-gRNA(HPRT) with a guide RNA tar-
geting the RNU12 gene (GCGGGTAAAGGTCGCCCT
CA). The original plasmid (Addgene #79620) was a gift
from Dr. Akihiko Kondo. To enable more efficient enrich-
ment of transfected cells, the G418 cassette in this plasmid
was deleted by PCR, with simultaneous introduction of a
BsrGI site. Subsequently a puromycin cassette was cloned
into the plasmid using XbaI and BsrGI sites.
Cell culture, treatments and transfection
HEK293 and HeLa cells were cultured in DMEM supple-
mented with 10% FBS, 1% penicillin–streptomycin and 2
mM L-glutamine. Plasmid transfections were carried out
using Lipofectamine 2000 (Thermo Fisher). For tag-U12
experiments, each pUC19-RNU12-5′tag construct was co-
transfected at a 3:1 ratio with pAVU6+27-F30-2xdBroccoli
(Addgene #66842), a gift from Dr Samie Jaffrey. siRNA
reverse transfections were carried out using Lipofectamine
RNAiMAX (Thermo Fisher) and 30 nM final concentra-
tion of siRNA, followed by a 48 h incubation before RNA
extraction with Trizol. siRNAs were purchased from Dhar-
macon or Sigma-Aldrich and their sequences are listed in
Supplementary Table S1. For RNA half-life measurement,
HEK293 cells at ∼50% confluency were treated with 5
g/ml actinomycin D (Sigma-Aldrich) and lysed with Tri-
zol at the indicated time points.
Genome editing using the Target-AID method
HEK293 cells were transfected with 4 g of the Targed-
AID-puro-RNU12 plasmid using Lipofectamine 2000.
Puromycin selection was applied at a 3 g/ml final con-
centration for 72 h, starting 24 h after transfection. Af-
ter selection, genomic DNA was extracted using the Nu-
cleoSpin Tissue kit (Macherey–Nagel). The RNU12 locus
was amplified using primers U12-surv-F and U12-surv-R
(Supplementary Table S1). Editing was detected using the
Surveyor Mutation Detection Kit (IDT) according to the
manufacturer’s instructions and confirmed by Sanger se-
quencing. Single-cell clones were obtained by limiting di-
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Figure 1. Construction of a HEK293 cell line model of the 84C>T U12 snRNA mutation. (A) Secondary structure and functional elements of human U12
snRNA. (B) Introducing the 84C>T mutation into the RNU12 gene using base editing. Bottom: The single guide RNA (sgRNA) and the PAM site used
for editing the RNU12 gene are shown. The orange gradient marks the window where cytosine deamination is expected to take place using the Target-AID
method (highest efficiency at -17 to -19 upstream of the PAM site). Left: Sequencing chromatograms of the deamination site from wild-type HEK293 cells,
cells transfected with the Target-AID editing plasmid and selected with puromycin and a single-cell clone homozygous for the 84C>T mutation. Right:
Analysis of the RNU12 locus by Surveyor assay in HEK293 cell pools transfected with a modified Target-AID plasmid carrying negative control (Chinese
hamster hprt; lanes 1–2) or RNU12 sgRNA (lanes 3–4) and optionally selected with puromycin (lanes 5–6). Digestion of heteroduplexes with a mismatch
at position +84 of the RNU12 gene is expected to result in fragments of 411 bp and 144 bp.
and screened for editing using Surveyor assay and sequenc-
ing of the RNU12 locus.
Immunoprecipitations
Anti-Sm (Y12; Invitrogen, MA5-13449) and anti-TMG (a
gift from Dr Cindy Will, MPI Göttingen) antibodies were
used for immunoprecipitation experiments. Following 48
h of siRNA transfection in 6-well plate format, HEK293
cells were scraped in 300 l lysis buffer (20 mM HEPES,
pH 7.4, 137 mM NaCl, 10% glycerol, 1% NP-40, 2 mM
EDTA, 1× cOmplete protease inhibitor cocktail (Roche),
0.5 U/l RiboLock) and sonicated 5 × 30 s using a Biorup-
tor Twin sonicator. Lysates were cleared by centrifugation
(16 000 g, 15 min) and then incubated with antibodies (2
g) bound to magnetic beads (Dynabeads Protein G) for 1 h
at 4◦C. Immunoprecipitation with anti-TMG antibody was
carried out using 20 g of Trizol-extracted total RNA in
20 mM HEPES, pH 7.4, 150 mM NaCl, 0.1% NP-40. After
five washes with 200 l lysis buffer, co-immunoprecipitated
RNA was eluted from the beads by Proteinase K digestion
and purified by phenol-chloroform extraction and ethanol
precipitation.
Cellular fractionation
Cellular fractionation was carried out using the REAP
method as described (23). Total cell and cytoplasmic
fractions were digested with proteinase K and extracted
with phenol:chloroform:isoamyl alcohol and chloro-
form:isoamyl alcohol, followed by ethanol precipitation.
RNA extraction from the nuclear pellet was carried out
using TRIzol method.
Northern blot
Typically, 2–3 g of Trizol-extracted total RNA was run on
a 6–8% urea-polyacrylamide gel, transferred onto Hybond-
XL nylon membrane using an Owl semi-dry or tank blotter
and crosslinked with UV light using the UVP CL-1000 Ul-
traviolet Crosslinker. Membranes were probed either with
5 × 106 cpm of [ -32P]-ATP-labeled LNA/DNA or DNA
oligonucleotides listed in Supplementary Table S1 or ribo-
probes produced by in vitro transcription with T7/T3/SP6
RNA polymerase in the presence of [-32P]-UTP (ma-
jor spliceosomal snRNAs in Figure 2A). Hybridization of
DNA oligonucleotide probes was carried out overnight at
37 or 42◦C (probes for major spliceosomal snRNAs and
U5 snRNA) in 6xSSC, 25 mM Na2HPO4/NaH2PO4 (pH
7.4), 0.5% SDS, 5× Denhardt’s solution, 150 g/ml yeast
RNA (Roche). For LNA-containing oligonucleotide probes
and riboprobes, hybridization was carried out overnight at
45◦C and 50% formamide was included in the hybridization
buffer. Membranes probed with DNA probes were washed
at room temperature in 2× SSC, 0.1% SDS and 0.5× SSC,
0.1% SDS, 15 min each. For LNA and RNA probes, two
additional 15 min washes with 0.1× SSC, 0.1% SDS were
included, the final wash done at 60◦C. Blots were exposed
on imaging plates and scanned using either Typhoon FLA
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Figure 2. The 84C>U mutation leads to destabilization of the U12 snRNA. (A) Northern blot analysis of spliceosomal snRNA levels in RNU12+/+and
RNU1284T/84T cells. Shown are three independent samples from RNU12+/+ HEK293 cells (lanes 1–3) and samples from three different RNU1284T/84T
HEK293 single-cell clones (lanes 4–6). The same northern blot membrane was sequentially stripped and reprobed with different individual snRNA probes.
For data visualization purposes, the signal intensity in the entire membrane (containing both RNU12+/+and RNU1284T/84T samples) was adjusted so that
the RNU12+/+ lanes showed similar intensities between the different snRNAs. (B) Quantification of snRNA northern blot data from A. The quantification
is based on measurements from three total RNA samples from RNU12+/+ HEK293 cells, three samples from RNU1284T/+ HEK293 single-cell clones and
eight samples from RNU1284T/84T HEK293 single-cell clones. Loading was normalized by dividing all band intensities by the sum of U1 and U2 intensities
averaged across all samples and the average intensity of the WT samples was then set to 1 for each snRNA. Error bars represent standard deviation.
Statistical significance levels (ns: P > 0.05, [∗] P ≤ 0.05, [∗∗] P ≤ 0.01, [∗∗∗] P ≤ 0.001) from one-way ANOVA followed by Tukey’s test are indicated.
(C) Levels of exogenously expressed WT and 84C>U-mutant U12 snRNA in HeLa, U2OS and HEK293 cell lines. Tag-U12 constructs or empty pUC19
vector were co-transfected into each cell line together with a plasmid for expressing the F30-2xdBroccoli aptamer (61) used as a transfection control. (D)
Actinomycin D treatment of RNU12+/+ and RNU1284T/84T HEK293 cells. Cells were treated with 5 g/ml actinomycin D for 0–8 h and harvested at the
indicated time points. Shown are northern blots probed with U12 and U6atac snRNA-specific probes. (E) Decay kinetics of the U12 and U6atac snRNAs
in RNU12+/+ and RNU1284T/84T HEK293 cells upon actinomycin D treatment. The individual time series were normalized by setting the mean value of
zero hour time point to 1.0. Statistical significance levels, determined using Student’s t-test, refer to comparisons between U12WT and U1284C>U at the
indicated time points.
Primer extension
Total RNA (20 g) was ethanol precipitated with 1 pmol of
32P-labeled LNA primer (U12-RT-LNA-17) and annealed
by heating to 95◦C followed by slow cooling to 50◦C. An-
nealing was carried out in 50 mM Tris–HCl (pH 8.3), 50
mM KCl, 1 mM EDTA. For extension, samples were ad-
justed to 50 mM Tris–HCl (pH 8.3), 75 mM KCl, 3 mM
MgCl2, 10 mM DTT, 0.5 mM dNTPs, 50 g/ml actino-
mycin D, 1 U/l RiboLock, 2 U/l Maxima H Minus RT.
Extension reactions were incubated at 50◦C for 30 min and
terminated at 85◦C for 5 min. After extension, template
RNA was digested with RNase H and RNase A and the re-
actions were purified by phenol-chloroform (pH 7) extrac-
tion and ethanol precipitation. Extension products were an-
alyzed on a 9% urea–polyacrylamide gel, which was dried,
exposed on an imaging plate and scanned using Typhoon
FLA 9400.
RT-PCR
TRIzol-extracted RNA (1 g) was treated with RQ1
RNase-Free DNase (Promega) to remove any contaminat-
ing genomic DNA. cDNA synthesis from 1 g DNase-
treated total RNA was carried out using Maxima H Mi-
nus Reverse Transcriptase (Thermo Fisher Scientific) and
ReadyMade random hexamer primers (IDT) according to
the manufacturer’s instructions. PCRs were carried out us-
ing Phire Hot Start II DNA Polymerase (Thermo Fisher
Scientific) and primers listed in Supplementary Table S1.
Cloning and sequencing of U12 snRNA fragments
U12 snRNA was pulled down from 25 g total RNA us-
ing 100 pmol of a biotinylated DNA oligo (hU12 1-23 B)
and 60 l of Dynabeads Streptavidin M270 beads. Beads
were treated with RQ1 DNAse and then digested with Pro-
teinase K to elute bound RNA. After removing beads, sam-
ples were extracted once with phenol:chloroform:isoamyl
alcohol (25:24:1, pH 4.8) and ethanol precipitated. The S-
RNA cFP loop oligo was pre-adenylated using 5′ DNA
adenylation Kit (NEB). 5 pmol of the pre-adenylated oligo
was then ligated to the 3′ ends of pulled down RNAs using
200 U of truncated T4 RNA Ligase 2 (NEB) at 16◦C for
16 h in a 10 l reaction volume. The enzyme was heat in-
activated at 65◦C for 5 min. The hairpin structure formed
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synthesis, which was carried out using 200 U of Maxima
H Minus RT (Thermo Scientific) in a 20 l final volume at
50◦C for 30 min, followed by heat inactivation at 85◦C for
5 min. The RNA template was eliminated by digestion with
RNase H. 5 pmol of annealed TruSeqP7/TruSeqP7c oligos
were then ligated to the 3′ end of the cDNA using 30 U of
T4 DNA ligase (Thermo Scientific) at 16◦C for 16 h in a
30 l reaction volume. The ligase was heat inactivated and
the samples were treated with 1 U of USER enzyme (NEB)
at 37◦C for 30 min. 5 l the cDNA was used for RT-PCR
with primers U12-lig1 and U12-lig2. Samples were run on
a 3.5% MetaPhor agarose gel, bands excised and DNA ex-
tracted. The purified PCR products were cloned using Zero
Blunt TOPO PCR Cloning Kit (Thermo Fisher Scientific)
and DNA from individual colonies analyzed by Sanger se-
quencing.
RESULTS
Construction of a cell line model of RNU12-mutant cerebel-
lar ataxia
To study how the U12 snRNA mutation affects minor
spliceosome function, we first introduced the 84C>T mu-
tation into the genome of the HEK293 cell line using
CRISPR/Cas9 genome editing. As C84 is located 19 nu-
cleotides upstream of an AGG PAM site, we were able to
utilize the Target-AID method (24) in which a specific guide
RNA is used to target a fusion of Cas9 and activation-
induced deaminase (AID) to the locus of interest. This en-
ables specific deamination of cytosines within a narrow edit-
ing window centered at -18 relative to a PAM site (Figure
1B). We modified the system by replacing the G418 cas-
sette in the original Target-AID plasmid with a puromycin
cassette to allow for more efficient selection of transiently
transfected cells. Analysis of the RNU12 locus by mismatch
cleavage assay and Sanger sequencing after transfection re-
vealed efficient deamination at position –19 from the PAM
site, corresponding to the 84C>T mutation (Figure 1B).
Having confirmed editing at the transfected cell pool level,
we carried out cloning by limiting dilution and screened
the resulting clones for the presence of the mutation. We
were readily able to obtain both heterozygous and homozy-
gous 84C>T mutant cell lines, with 90% (45/50) of screened
single-cell clones being positive for editing in the RNU12 lo-
cus as judged by mismatch cleavage assay and ∼60% (11/18)
of the positive clones analyzed by Sanger sequencing being
homozygous for the 84C>T mutation. From here on, we
will refer HEK293 cells carrying homozygous 84C>T mu-
tation as RNU1284T/84T, heterozygous as RNU1284T/+ and
wild-type cells as RNU12+/+. Similarly, the 84C>U-mutant
U12 snRNA will be referred to as U1284C>U and the wild-
type snRNA as U12WT.
The 84C>U mutation leads to reduced U12 snRNA stability
in human cell lines
In the original report describing the 84C>T RNU12 muta-
tion (20), mononuclear blood cells from patients were re-
ported to exhibit elevated levels of U12 snRNA compared
to healthy wild-type individuals. Thus, we measured the lev-
els of minor and major snRNAs in several homozygous
and heterozygous HEK293 cell lines carrying the 84C>T
mutation (Figure 2A, B). In contrast to the earlier re-
port, our northern blot analyses revealed 49% and 62% re-
duction in steady-state U12 snRNA levels in RNU1284T/+
and RNU1284T/84T clones, respectively. The reduced U12
snRNA levels with RNU1284T/84T clones were also con-
firmed by primer extension analysis (Supplementary Fig-
ure S1). Additionally, the levels of the U4atac snRNA were
slightly elevated in 75% (6/8) of the RNU1284T/84T clones
analyzed (P = 0.027; Figure 2A, B), reminiscent of the up-
regulation of U4atac in isolated growth hormone deficiency
patients with RNPC3 mutations (18). Levels of the other
spliceosomal snRNAs were not significantly different from
wild type HEK293 cells. Furthermore, we also confirmed
that the RNU1284T/84T mutation leads to aberrant splicing
of U12-type introns, particularly activation of cryptic U2-
type splice sites near the U12-type introns (Supplementary
Figure S2), similarly as described earlier (25,26).
To test the generality of the observed reduction in U12
snRNA levels, we created a reporter construct in which
the U12 snRNA is expressed from a genomic fragment
that includes the native U12 promoter elements and 3′
flanking region (Supplementary Figure S3A). The 5′ end
of the U12 snRNA carries a 15 nt sequence tag, allow-
ing the exogenously expressed U12 snRNA to be distin-
guished from endogenous U12 snRNA by size on a north-
ern blot or using tag-specific probe (Figure 2C, Supple-
mentary Figure S3). The tag is predicted to remain single-
stranded by RNAfold (27; Supplementary Figure S3B) and
should thus not affect the folding of tagged U12 snRNA.
We transfected WT and 84C>T-mutant versions of the tag-
U12 constructs into HeLa (Figure 2C, lanes 1–3), U2OS
(lanes 4–6) and HEK293 cells (lanes 7–9) and assayed tag-
U12 snRNA levels by northern blot. Importantly, com-
pared to the WT snRNA, exogenously expressed 84C>U-
mutant U12 snRNA consistently exhibited reduced steady-
state levels in all three cell lines tested (Figure 2C), confirm-
ing that the reduction in steady-state levels is not restricted
to our edited HEK293 cell lines, and can be recapitulated
using a reporter system.
Next, we asked whether the observed reduction in steady-
state levels is due to reduced stability of the mutant snRNA,
and treated RNU12+/+ and RNU1284T/84T cells with the
transcriptional inhibitor actinomycin D for 0–8 h and mea-
sured U12 snRNA levels at specific time points by north-
ern blot (Figure 2D, E). Spliceosomal snRNAs have been
reported to exhibit very long half-lives, with the notable
exception of the U6atac snRNA, which turns over rapidly
(28,29). Consistently, the wild-type U12 snRNA remained
essentially stable for the duration of the experiment (8 h;
Figure 2D, E). Compared to the WT snRNA, U1284C>U
displayed accelerated decay kinetics (t1/2 = 5.6 h), while the
highly unstable U6atac snRNA exhibited similar half-lives
in both wild-type and mutant HEK293 cells (t1/2 = 1.0 h
and 1.2 h, respectively) that are consistent with a previous
report (29). These results show that the 84C>U mutation
has a destabilizing effect on the U12 snRNA.
Truncated U12 snRNAs accumulate in 84C>T-mutant cells
To ask if weakening of the terminal base-pair of stem-
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of nucleotide combinations at positions C84 and G150 us-
ing the 5′-tagged U12 snRNA expression construct and
measured the steady-state levels of the tagged snRNAs in
HeLa cells using northern analysis. Interestingly, our probes
specific to the 5′ tag revealed, in addition to full-length
U12 snRNA, additional shorter bands (Figure 3A, middle
panel) that were more abundant with several of the muta-
tions tested. Significantly, these bands were also detected
in the RNU1284T/84T cell lines with 5′-specific, but not 3′-
specific probe. Consistently, cloning and sequence analy-
sis revealed that the shorter RNA fragments represent U12
snRNAs that were truncated from the 3′-end (Figure 3B,
Supplementary Figure S4A, B). These characteristics led us
to hypothesize that the bands most likely represent stable
decay intermediates arising from 3′-to-5′ exonucleolytic de-
cay.
Mutational analysis revealed that any change that dis-
rupts the base-pairing of SLIII terminal nucleotides reduce
the full-length U12 snRNA levels by up to ∼80% (Figure
3A, lanes 7–9). Furthermore, the levels of the truncated U12
snRNAs are generally negatively correlated with the full-
length U12 snRNA and account for a significant fraction
(up to 41%) of the total cellular U12. Interestingly, while in-
version of the terminal C–G base pair to G–C shows close to
WT tag-U12 levels, a U–A base-pair at this position shows
similar tag-U12 levels as the EOCA disease mutation lead-
ing to a U–G base-pair (n.s., ANOVA). Together these re-
sults suggest that the stability of the terminal base-pair of
the SLIII is an important determinant of the overall sta-
bility of U12 snRNA. The only outlier is the noncanoni-
cal G–G pair that shows similar U12 snRNA levels as U–
A and U–G pairs (n.s., ANOVA), but lacks the increase in
U12 snRNA fragments. The reason for this is unknown,
but a possible explanation may be that altered stacking
interactions in the G-rich region of the lower stem may
compensate for the loss of base-pairing interactions (see
Figure 3B).
The truncated species are also present in HEK293 cells
carrying WT U12 allele. In that case the truncated forms ac-
counted for only a minute fraction (∼0.3%) of the total U12
snRNA as compared to the ∼13.5% with 84C>T mutation
(Figure 3C). In both cases, knockdown of the NEXT com-
plex (see below) significantly increased the levels of the de-
cay intermediates. The U12 snRNA fragments contain the
Sm site but are missing most of the stem-loop III sequence
(Figure 3B). This is in contrast to previously described trun-
cated forms of the U1 and U2 snRNAs, which lack the Sm
site (30,31). Unlike truncated forms of U1 snRNA, which
were shown to be highly unstable (30), the most abundant
U12 snRNA fragments of ∼90 nt remained stable for 8 h of
actinomycin D treatment (see figures 4D and F); however,
the lower-abundance fragments appeared to decay faster, al-
though their very low levels made half-life estimation un-
feasible. We conclude that the decay of the mutant U12
snRNAs utilizes a natural pathway also acting on WT U12
snRNA, as the truncated decay intermediates can also be
detected in WT HEK293 cells. However, in RNU1284T/84T
cells a significant fraction of U12 snRNA is targeted via
this pathway, thus lowering the steady-state levels of U12
snRNA.
U12 snRNA fragments are formed after cytoplasmic snRNP
biogenesis steps
We next investigated whether the 84C>U mutation affects,
in addition to the accelerated decay, also the overall U12
snRNP biogenesis. snRNPs form through a complex bio-
genesis pathway that is distinct for Sm-class and LSm-class
snRNPs (reviewed in 32,33). Sm-class snRNAs, which in-
clude all spliceosomal snRNAs except U6 and U6atac, are
transcribed by RNA polymerase II and cleaved by the In-
tegrator complex to generate precursor snRNAs with a 3′
extension (34,35), which are subsequently exported to the
cytoplasm for further biogenesis steps. These include assem-
bly of the Sm ring on the Sm site of the snRNA and hyper-
methylation of the 7-methylguanosine cap (m7G) to 2,2,7-
trimethylguanosine (m2,2,7G or TMG). We asked whether
the mutant U12 snRNA and the U12 fragments have suc-
cessfully undergone the cytoplasmic steps of snRNP bio-
genesis by immunoprecipitation with anti-Sm (Y12) and
anti-2,2,7-trimethylguanosine cap (anti-TMG) antibodies.
We found that both the full-length WT and 84C>U-mutant
snRNAs and their truncated forms were all efficiently im-
munoprecipitated, not only with the anti-Sm antibody (Fig-
ure 3C, lanes 7–12) but also with anti-TMG antibody (Fig-
ure 3D). This suggests that full-length U12 snRNA and the
truncated forms successfully complete both the Sm core as-
sembly and the subsequent 5′ cap hypermethylation steps of
the snRNP assembly that take place in cytoplasm (36,37).
Consistent with the role of Sm core and TMG cap as a bi-
partite signal for nuclear import of snRNPs (38,39), nucle-
ocytoplasmic fractionation of RNU1284T/84T cells revealed
that U12 snRNA fragments are predominantly located in
the nucleus, with only a minor sub-population detected in
the cytoplasm (Figure 3E).
The prime candidate mediating U12 snRNA decay is the
nuclear exosome targeting (NEXT) complex. This trimeric
cofactor complex consists of MTR4, RBM7 and ZCCHC8
proteins (40) and has been shown to target snRNAs for nu-
clear exosome-mediated decay (41). To test if the NEXT
complex is involved in the decay of 84C>U U12 snRNA,
we knocked down MTR4 and RBM7 in RNU12+/+ and
RNU1284T/84T cells (Supplementary Figure S5). Northern
analysis revealed a mild upregulation of the full-length U12
snRNA with MTR4 and RBM7 knockdowns in RNU12+/+
cells (1.17-fold increase, P = 0.016) while the result in
RNU1284T/84T cells was not conclusive due to elevated vari-
ation (1.4-fold, n.s.) (Figure 4A, B). In contrast, the levels
of U12 snRNA fragments increased significantly both in to-
tal RNA pool (Figure 3C, lanes 1–6) and anti-Sm immuno-
precipitates (Figure 3C, lanes 7–12) after MTR4 or RBM7
knockdown, and also in anti-TMG immunoprecipitates af-
ter MTR4 knockdown (Figure 3D, lanes 5–10). Compared
to non-targeting siRNA control, knockdown of MTR4 re-
sulted in a 4-fold (n.s.) and 3-fold (P <0.0001) increase in
fragment levels in RNU12+/+ and RNU1284T/84T cells, re-
spectively (Figure 4A, lanes 1, 2, 5, 6; Figure 4B). The per-
centage of U12 fragments increased from 0.3% to 0.9% in
RNU12+/+ cells, while in RNU1284T/84T cells the percentage
increased from 13.5% to 24.1% (Figure 4C). This data sug-
gested that the NEXT complex is involved in targeting the
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Figure 3. Identification and characterization of truncated U12 snRNAs in human cells. (A) Effects of mutations in the terminal base-pair of U12 snRNA
stem-loop III on full-length U12 and U12 fragment levels. Top: Plasmid constructs for expressing tag-U12 with various combinations of nucleotides in
the 84 and 150 positions were transfected into HeLa cells. Co-transfected F30-2xdBroccoli expression plasmid served as a transfection control. Total
RNA from transfected HeLa cells was analyzed by northern blot with U12, U11, tag-U12 and Broccoli probes. Bottom: Quantification of full-length U12
(blue) and U12 fragment (orange) levels. Band intensities were normalized by the sum of all band intensities of each replicate, and the mean full-length
U12 snRNA signal of WT tag-U12 (C-G) was then set to 1. Statistical significance was determined using one-way ANOVA followed by Dunnett’s test.
Significance levels above each bar refer to comparisons between WT tag-U12 and the indicated variant. Based on pair-wise comparisons (ANOVA with
Tukey’s test), differences in fragment levels between the group of variants showing low levels of tag-U12 fragments (C-G, G-C, G-G) and the group with
high levels of fragments (U–G, U–A, C–C, U–C, C–A) were all statistically significant (*–***). In contrast, none of the pair-wise comparisons within the
two groups showed statistically significant differences in fragment levels. (B) Location of truncation sites of U12 snRNA fragments determined by Sanger
sequencing. See Supplementary Figure S4A and B for details. (C) Detection of short U12 snRNA species in association with Sm proteins. Forty eight
hours after control, MTR4 or RBM7 siRNA transfection, anti-Sm immunoprecipitations were carried out using total cell lysates from RNU12+/+ and
RNU1284T/84T cells. RNA extracted from input and IP samples was analyzed by northern blotting with a probe specific to U12 (1–31). The U1 and 7SK
snRNA were also analyzed as controls. The anti-Sm antibody immunoprecipitated the U1 snRNA, whereas the 7SK snRNA, which does not associate with
Sm proteins, was only weakly detected. (D) U12 snRNA fragments carry a trimethylated 5′ cap. Anti-TMG immunoprecipitation was carried out using
total RNA from RNU12+/+ and RNU1284T/84T cells transfected with control or MTR4 siRNA. Northern blotting was carried out with U12 (1–31) and
U2 snRNA (35–66) probes. (E) Cytoplasmic–nuclear distribution of U12 snRNA fragments. RNU1284T/84T were fractionated into total (T), cytoplasmic
(C) and nuclear (N) fractions and RNA from the fractions analyzed by northern blot and RT-PCR as indicated. tRNA(Glu) served as a marker for the
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Figure 4. TOE1 is required for the formation of U12 snRNA fragments. (A) TOE1 plays a role in the formation or maintenance of U12 snRNA fragments.
Total RNA from RNU12+/+ and RNU1284T/84T cells transfected with control, MTR4, TOE1 or MTR4 and TOE1 siRNAs was analyzed by northern
blot. (B) Effects of MTR4 and TOE1 knockdowns on full-length U12 snRNA levels (blue) and U12 snRNA fragment levels (orange). Quantification and
normalization was carried out as described in Figure 3A. Statistical significance was determined by one-way ANOVA followed by Tukey’s test. (C) Effects
of MTR4 and TOE1 knockdowns on the percentage of U12 snRNA fragments of total U12 snRNA. (D) Impact of MTR4 and TOE1 knockdowns on the
stability of the U1284C>U snRNA and U12 snRNA fragments. 48 h after siRNA transfection, RNU1284T/84T cells were treated with 5 g/ml actinomycin
D and harvested at the indicated time points. Total RNA was analyzed by northern blot using U12-specific probe binding to 5′ end of the snRNA.
(E) Decay kinetics of the full-length U1284C>U snRNA in MTR4, TOE1 and MTR4/TOE1 double knockdown RNU1284T/84T cells. Quantification of
northern blot data from three independent experiments represented in panel D. Full-length U12 snRNA signal was normalized to the U2 snRNA signal
and the 0 h sample of each set of samples was set to 1. (F) Time-dependent accumulation of U12 snRNA fragments during transcriptional inhibition. The
quantification is based on the highest abundance (∼90 nt) U12 snRNA fragments only and the data is derived from three independent experiments. Loading
was normalized by U2 snRNA signal. For each replicate, the 0 h siCTRL sample was set to 1 to visualize both accumulation and absolute differences in
U12 snRNA fragment levels between siRNA treatments.
Recent work revealed TOE1, a primarily Cajal body-
localized deadenylase with nucleo-cytoplasmic shuttling ac-
tivity (42,43), as the enzyme responsible for the 3′ trimming
of human snRNA precursors to their mature length (44,45).
TOE1 thus represents another 3′-to-5′ exonucleolytic activ-
ity targeting the 3′ end of snRNAs. Somewhat surprisingly
and in contrast to NEXT complex knockdowns, TOE1
knockdown led to a decrease in the levels of the U12 snRNA
fragments in both WT and mutant HEK293 cells (Fig-
ure 4A–C). In RNU1284T/84T cells TOE1 knockdown re-
sulted in a 6.9-fold decrease in U12 fragment levels (P =
0.049), reducing the percentage of fragments from 13.5%
to 1.6%. Similarly, TOE1 knockdown in RNU12+/+ cells
led to almost complete disappearance of the U12 frag-
ments (Figure 4A, C). Combining siMTR4 with siTOE1
resulted in slightly elevated U12 fragment levels than with
siTOE1 alone, but well below siCTRL levels, while full-
length U12 levels in RNU1284T/84T cells showed a significant
(P = 0.0017) 1.8-fold increase compared to siCTRL (Fig-
ures 4A, lane 8; B). The results with U12 snRNA fragments
suggest that the decay of the mutated U12 snRNA is initi-
ated by TOE1, which forms the 3′-truncated U12 snRNA
fragments that are subsequently targeted for further decay
by the NEXT complex.
Half-life measurements (Figures 4D–F) provide further
insight to the role of TOE1 and NEXT complex in the de-
cay of the U1284C>U snRNA. Knockdown of MTR4 led
to initial stabilization not only of the full-length U1284C>U
snRNA but also U12 snRNA fragments, suggesting that the
nuclear exosome, targeted by the NEXT complex, has a sig-
nificant role in the decay of full-length U1284C>U snRNA
(Figure 4D, E), but also in the final decay of the U12 snRNA
fragments (Figure 4D, F). In contrast, the reduced half-
life of full-length U1284C>U snRNA observed with TOE1
knockdown that is restored to control knockdown levels
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suggests that TOE1 has also a role in counteracting the
exosome-dependent decay. We do note that since the com-
bined NEXT complex and TOE1 knockdowns (Figure 4B)
had only a minor effect on restoring the levels of full-length
U1284C>U snRNA, other RNA decay pathways are likely to
play a role in the decay of U1284C>U. Indeed, several path-
ways have been implicated in the quality control and normal
turnover of snRNAs (46–50).
SLIII point mutations destabilize U12 snRNA
The dbSNP and gnomAD databases (51,52) list a signifi-
cant number of SNP and other variants in U12 snRNA in-
cluding the SLIII region (Supplementary Table S2). Con-
sidering the magnitude of destabilization induced by single-
nucleotide changes in the very stable stem-loop III (Figure
3A), we reasoned that other U12 snRNA alleles segregat-
ing in human population, particularly those with nucleotide
substitutions in the stem–loop III may have a similar effect
on U12 snRNA stability. These could include, in addition
to SNPs directly affecting the base of SLIII, also other vari-
ants that change the folding of SLIII and potentially result
in targeting by TOE1 and/or NEXT complex. To test this
possibility, we sampled a subset of the dbSNP/gnomAD
mutations and other mutations (Figure 5B) predicted to
perturb the structure of the snRNA (Supplementary Table
S3). For predictions we used the RNA2DMut tool (53) that
estimates the effect of all possible point mutations on the
secondary structure of an input RNA, providing a statisti-
cal metric describing the structural ensemble (ED, ensem-
ble diversity) as well as minimum free energy and centroid
secondary structures. Using the tag-U12 reporter, we ana-
lyzed a panel of mutations in the 3′ domain of U12 snRNA
which all showed elevated ED values compared to the WT
structure (ED), indicating presence of multiple structural
conformations or lack of structure (Figure 5).
Interestingly, all the analyzed variants showed lower
steady-state tag-U12 levels compared to the WT tag-U12
snRNA (Figure 5), regardless of whether they were lo-
cated at the base of SLIII or elsewhere. In particular, muta-
tions in the G85–C149 (85G>A, 149C>A) and G86–C148
(86G>U, 148C>U) base pairs at the base of SLIII had a
very dramatic effect, leading to 84–97% reduction in the
full-length tag-U12 signal (Figure 5A, lanes 5, 6, 13, 14;
Figure 5C). Furthermore, several other mutations located
further up in the SLIII stem showed similarly reduced U12
snRNA levels as the original 84C>U mutation. In addition
to the 84C>U mutation, a significant increase in tag-U12
fragment levels was only observed with the 148C>U vari-
ant. This data indicates that in addition to 84C>U, multiple
additional mutations in the SLIII, a subset of which are al-
ready segregating in human population, can destabilize U12
snRNA and are thus alone or as compound heterozygotes a
potential cause of additional minor spliceosome-associated
human diseases.
DISCUSSION
In this study, we have investigated the molecular mecha-
nism underlying Early onset cerebellar ataxia caused by
the 84C>T mutation in the RNU12 gene encoding U12
snRNA, a component of the minor spliceosome. We show
that the RNU12 84C>T mutation leads to a significant re-
duction in the half-life of U12 snRNA and consequently
∼60% decrease in the steady-state levels of the U12 snRNA
not only in a HEK293 cell model carrying homozygous
84C>T mutation, but also in several other cell lines. Ad-
ditionally, we discovered that HEK293 cells carrying the
mutated U12 snRNA accumulate stable decay intermedi-
ates that lack the 3′ SLIII of the U12 snRNA. Further-
more, we show that efficient decay of the U1284C>U snRNA
requires TOE1 deadenylase and NEXT complex activities.
Given that both the full-length U1284C>U snRNA and the
decay intermediates carry a TMG cap and are associated
with Sm proteins, we propose a model (Figure 6) where the
decay of the U1284C>U snRNA takes place in the nucleus
after the cytoplasmic steps of the snRNA biogenesis have
been completed. This decay/quality control pathway oper-
ates at low levels in WT cells, but the mutations that com-
promise the integrity of the SLIII shift the balance towards
the decay pathway.
Our observation that the 84C>T mutation leads to a re-
duction in the half-life and consequently reduced steady-
state levels of the U12 snRNA in multiple cell lines is in con-
trast to the finding by Elsaid et al. (20) who used qRT-PCR
analysis of patient mononuclear blood lymphocytes, and in-
stead reported upregulation in the U1284C>U snRNA lev-
els. Additionally, while we also detect minor-intron specific
splicing defects, those are less prominent than the ones de-
scribed in Elsaid et al. (20) work. Such strong tissue and cell
type-specific effects on intron retention levels have also been
described with MOPD1/TALS patient cells containing mu-
tations in U4atac snRNA (54). In contrast, the contradict-
ing outcome on U1284C>U snRNA levels between the two
studies either suggest differences between the proliferating
cells in culture and patient-derived peripheral blood lym-
phocytes or, alternatively, technical differences between the
two studies. The U12 snRNA downregulation in this study
was observed by two different methods (northern analysis
using multiple probes and primer extension analysis). Fur-
thermore, the NEXT complex and TOE1-dependent desta-
bilization of the U1284C>U snRNA, observed in this study,
is consistent with the recent work on snRNA decay path-
ways (45). The 2-fold increase in U1284C>U snRNA lev-
els observed in Elsaid et al. (20) in lymphocytes would re-
quire either increased stability or transcriptional upregu-
lation of the U1284C>U snRNA. However, the location of
the 84C>T mutation outside of the known promoter re-
gion (55,56) argues against the possibility that the muta-
tion could lead to transcriptional upregulation. Similarly,
the already high stability of U12WT snRNA (29; Figure 2D,
E) questions whether the upregulation reported by Elsaid et
al. (20) is achievable by further increases in stability, unless
there are lymphocyte-specific biological mechanisms for up-
regulation that are also shared with the cells of cerebellar
tissue.
The observation that U1284C>U snRNA is specifically tar-
geted for 3′-to-5′ exonucleolytic decay by TOE1 and the
NEXT complex generating relatively stable decay interme-
diates that terminate downstream of the Sm-site provide an
insight to the mechanism of the decay pathway. The kinetics
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Figure 5. Effect of stem-loop III variants on U12 snRNA levels. (A) Effects of single-nucleotide variants in the stem-loop III of U12 snRNA on full-length
tag-U12 and tag-U12 fragment levels. (B) Impact of the analyzed variants on tag-U12 levels in relation to location on the stem-loop III. The color scale
indicates relative tag-U12 levels, with WT tag-U12 level set to 1 (green), and 0 (red) indicating complete loss of tag-U12 signal. (C) Effect of stem-loop III
variants on full-length tag-U12 levels (blue) and tag-U12 fragment levels (orange). Quantification and statistical testing were carried out as described for
Figure 3A.
ments after transcription inhibition (Figure 4F) suggests
that the 3′ end decay takes place only after nuclear reim-
port instead of the cytoplasmic phase of snRNA biogenesis
or immediately after transcription. This conclusion is con-
sistent with the localization of NEXT complex in nucleo-
plasm (40) and TOE1 in Cajal bodies (42,43), and further
supported by the presence of Sm core proteins and TMG
cap in the U1284C>U snRNA fragments, as these jointly con-
stitute the nuclear import signal for core snRNPs (38,39). In
contrast, defects in the early stages of the snRNA biogene-
sis are instead known to lead to a loss of cap hypermethy-
lation and inhibition of nuclear reimport and subsequent
rapid decay in cytoplasmic P-bodies, as observed with trun-
cated forms of U1 and U2 snRNAs (U1-tfs and U2-tfs, re-
spectively) that have errors in 3′ end formation and lack the
Sm-site (30,31).
TOE1 and the NEXT complex knockdown data further
suggests that the process is initiated by TOE1 which can,
particularly with the U1284C>U snRNA, ‘overtrim’ the 3′
end of the snRNA and lead to the formation of truncated
U12 snRNA fragments. The formation of discrete size U12
snRNA fragments that are visible in northern analysis most
likely reflects the inability of TOE1 to dislocate the Sm pro-
teins from the Sm site. This model is consistent with the
role of Sm proteins in protecting snRNA from degradation
(46,57) and is also supported by earlier RNase footprint-
ing experiments showing that the protective effect of Sm
proteins on U12 snRNA extends from the Sm site to the
beginning of SLIII (nucleotides 69–95) (58). To overcome
this protective barrier, subsequent action by nuclear exo-
some targeted by the NEXT complex is required for further
degradation of the U12 fragments.
What is the mechanistic basis of the U1284C>U destabi-
lization? The low levels of U12 snRNA decay intermediates
detected also in the WT cells argue that the accelerated de-
cay of U1284C>U snRNA is part of normal turnover pro-
cess. We hypothesize that with WT U12 snRNA, an infre-
quent stochastic process of terminal base-pair melting (59)
at the base of SLIII can expose an unpaired 3′ nucleotide
and provide an entry point for the exonuclease activities.
Based on our mutagenesis studies (Figure 3A) we suggest
that mutation of the terminal C-G base pair to U-G base-
pair at the base of SLIII exacerbates this melting process,
and thus provides an opening for TOE1 action. Support-
ing this hypothesis, the importance of the integrity of the
lower stem of SLIII on minor spliceosome function has also
been reported in an earlier mutagenesis study by Sikand and
Shukla (60).
In addition to the mutations that directly affect the sta-
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Figure 6. A model for U12 snRNA quality control/decay pathway. U12WT and U1284C>U snRNAs share the early steps of the snRNP biogenesis (Steps
1–3) that include transcription/early processing, cytoplasmic snRNP biogenesis steps, and nuclear import of the core snRNP. Subsequently, the U12WT
snRNA undergoes 3′ end trimming by TOE1 (Step 4a), giving rise to mature U12 snRNP. With U12WT the trimming with TOE1 can infrequently progress
too far (‘overtrimming’), causing low-level formation of truncated U12 snRNAs in WT cells (Step 4b) that are further degraded by the NEXT complex-
dependent exonucleolytic process (Step 5). Mutations in the SLIII, such as U1284C>U, lead to increased utilization of the overtrimming pathway, leading
to accumulation of truncated U12 snRNAs and decreased levels of full-length U12 snRNA. The U12 precursor structure, with extension indicated with
red dotted line has been drawn according to Yong et al. (63).
SLIII may also affect the stability through inducing more
extensive structural changes in SLIII. This possibility is
supported by our analysis of additional low-frequency U12
snRNA allelic variants with mutations in SLIII that segre-
gate in human population. A subset of those were predicted
by the RNA2DMut tool to increase the ensemble diversity
of the U12 snRNA, suggesting a possible SLIII folding het-
erogeneity that could also lead to the observed reduction in
the U12 snRNA steady-state levels. Given that several of the
analyzed SNP variants reduce U12 snRNA steady-state lev-
els to the same level as the 84C>T mutation, or even below,
our data thus support the possibility for additional disease-
causing variants within the RNU12 locus.
The role of TOE1 in initiating the U1284C>U decay is con-
sistent with recent studies (44,45) that have linked TOE1 not
only to snRNA maturation, but also quality control. Specif-
ically, a recent work by Lardelli and Lykke-Andersen (45)
has indicated that TOE1 and the NEXT complex can play
an antagonist role in snRNA decay, where TOE1 shields
the snRNA 3′ end from the nuclear exosome. Such compe-
tition between the two activities is consistent with our half-
life analyses (Figure 4D, E) where the MTR4 knockdown
stabilizes and TOE1 knockdown destabilizes the full-length
U1284C>U snRNA. It is possible that the role of TOE1 in ini-
tiating the decay of U1284C>U snRNA is also linked to the
tissue specificity of the disease. Significantly, mutations in
TOE1 have been shown to cause pontocerebellar hypopla-
sia (PCH7; 44) which, together with the EOCA mutation
in this study, suggests that specific cell type(s) in cerebellum
may have increased demand for TOE1 and other snRNA 3′
end processing activities that could make U1284C>U more
vulnerable for degradation. Alternatively or additionally, as
a variety of neuronal phenotypes is shared among the mi-
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RFMN and LWS with U4atac snRNA mutations, the cere-
bellar defect may rather be arising from splicing defects in
a specific set of genes carrying minor introns.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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